Skip to main content

Table 3 First-line Treatment of Invasive Aspergillosis: Prospective Controlled Trials

From: Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin - review of the literature

Study N= Design Treatment MDST (range) Response (CR+PR) Survival week 12
Herbrecht 277 op, rd AmB Desoxycholate 1-1.5 mg/kg 10 (1-84) 31.6% 57.9%
2002 NEJM    Vori 2 × 6 mg/kg d1 and 2 × 4 mg/kg d2+ i.v.* 77 (2-84) 52.8% 70.8%
Cornely 201 db, rd LAmB 3mg/kg (d1-14)
} op3mg/kg d 15 +
14 (1-60) 50% 72%
2007 CID    LAmB 10 mg/kg (d1-14) 15 (1-57) 46% 59%
Herbrecht 2010 BMT ** 24 op, sa Caspofungin 70mg d1/50 mg d2+ 24 33% 50%
Viscoli 2009JAC # 61 op, sa Caspofungin 70mg d1/50 mg d 2+ 15 (3-84) 33% 53%
  1. Abbreviations: op = open, rd = randomized, db = double blind, sa = single arm, MDST = Median duration of study drug treatment in days, * a switch to oral voriconazole was allowed after day 7, **allogeneic cohort of patients, # hematological malignancies and autologous transplantation